Similar articles for PMID: 18201810

Year	Number of Results
1974	1
1975	1
1976	3
1977	16
1978	13
1979	23
1980	31
1981	19
1982	28
1983	30
1984	25
1985	21
1986	23
1987	10
1988	24
1989	18
1990	13
1991	7
1992	10
1993	18
1994	10
1995	8
1996	6
1997	13
1998	11
1999	7
2000	5
2001	7
2002	6
2003	4
2004	14
2005	6
2006	10
2007	29
2008	27
2009	12
2010	7
2011	3
2012	3
2013	2
2014	3
2015	4
2016	1
2021	1
2022	3
2023	1
2024	0

1

Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.

Miyaoka T, Furuya M, Yasuda H, Hayashida M, Nishida A, Inagaki T, Horiguchi J. Miyaoka T, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):761-4. doi: 10.1016/j.pnpbp.2007.12.003. Epub 2007 Dec 14. Prog Neuropsychopharmacol Biol Psychiatry. 2008. PMID: 18201810 Clinical Trial.

2

Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label study.

Miyaoka T, Furuya M, Yasuda H, Hayashida M, Nishida A, Inagaki T, Horiguchi J. Miyaoka T, et al. Clin Neuropharmacol. 2009 Jan-Feb;32(1):6-9. doi: 10.1097/WNF.0b013e31817e08c3. Clin Neuropharmacol. 2009. PMID: 19471183 Clinical Trial.

3

Yi-gan san for the treatment of borderline personality disorder: an open-label study.

Miyaoka T, Furuya M, Yasuda H, Hayashia M, Inagaki T, Horiguchi J. Miyaoka T, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):150-4. doi: 10.1016/j.pnpbp.2007.07.026. Epub 2007 Aug 8. Prog Neuropsychopharmacol Biol Psychiatry. 2008. PMID: 17765378 Clinical Trial.

4

Yi-gan san for treatment of charles bonnet syndrome (visual hallucination due to vision loss): an open-label study.

Miyaoka T, Furuya M, Kristian L, Wake R, Kawakami K, Nagahama M, Kawano K, Ieda M, Tsuchie K, Horiguchi J. Miyaoka T, et al. Clin Neuropharmacol. 2011 Jan-Feb;34(1):24-7. doi: 10.1097/WNF.0b013e318206785a. Clin Neuropharmacol. 2011. PMID: 21164340 Clinical Trial.

5

[Clinical usage of Yi-gan san-schizophrenia, borderline personality disorder, dyskinesia etc-].

Horiguchi J. Horiguchi J. Seishin Shinkeigaku Zasshi. 2012;114(6):708-18. Seishin Shinkeigaku Zasshi. 2012. PMID: 23094294 Japanese.

6

Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.

Sirota P, Mosheva T, Shabtay H, Giladi N, Korczyn AD. Sirota P, et al. Am J Psychiatry. 2000 Feb;157(2):287-9. doi: 10.1176/appi.ajp.157.2.287. Am J Psychiatry. 2000. PMID: 10671405 Clinical Trial.

7

Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.

Bai YM, Yu SC, Lin CC. Bai YM, et al. J Clin Psychiatry. 2003 Nov;64(11):1342-8. J Clin Psychiatry. 2003. PMID: 14658949 Clinical Trial.

8

Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.

Lee JG, Shin BS, Lee YC, Park SW, Kim YH. Lee JG, et al. Psychiatry Clin Neurosci. 2007 Oct;61(5):509-14. doi: 10.1111/j.1440-1819.2007.01700.x. Psychiatry Clin Neurosci. 2007. PMID: 17875029 Free article. Clinical Trial.

9

Effect of Yi-Gan San on psychiatric symptoms and sleep structure at patients with behavioral and psychological symptoms of dementia.

Shinno H, Inami Y, Inagaki T, Nakamura Y, Horiguchi J. Shinno H, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):881-5. doi: 10.1016/j.pnpbp.2007.12.027. Epub 2008 Jan 11. Prog Neuropsychopharmacol Biol Psychiatry. 2008. PMID: 18243460 Clinical Trial.

10

A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.

Lohr JB, Caligiuri MP. Lohr JB, et al. J Clin Psychiatry. 1996 Apr;57(4):167-73. J Clin Psychiatry. 1996. PMID: 8601552 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

525 results

Results by year